转型先锋Lonza与药明生物引领医药CDMO行业，展望未来市场需求激增！

Swiss Lonza and China's WuXi Biologics have become leaders in the global and domestic biopharmaceutical CDMO industry, respectively. Founded in 1897, Lonza transformed from a hydroelectric power company to a CDMO giant, leveraging the pharmaceutical industry's rise. Meanwhile, WuXi Biologics, established in 2010, has rapidly climbed the ranks with CRDMO model, capital, technology, and customer advantage, bolstered by China's 2016 MAH policy. Both companies have seen significant growth, and their success stories are expected to inspire more players in the CDMO sector, as biotech advances push the industry forward.